Estrogen-responsive RING finger protein controls breast cancer growth

Journal of Steroid Biochemistry and Molecular Biology

Volumn 85, Issue 2-5, 2003, Pages 101-104

  Horie, Kuniko ^a   Urano, Tomohiko ^b   Ikeda, Kazuhiro ^a   Inoue, Satoshi ^a,b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

14 3 3 ; Breast cancer; Efp; Endocrine therapy; Estrogen; RBCC motif; RING finger; Ubiquitin protein ligase (E3)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ESTROGEN RECEPTOR; ESTROGEN RESPONSIVE RING FINGER PROTEIN; PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

BINDING SITE; BREAST CARCINOMA; CANCER GROWTH; CELL PROLIFERATION; CONFERENCE PAPER; DATA ANALYSIS; ENVIRONMENT; GENE CONTROL; GENE TARGETING; GENOME; HORMONAL THERAPY; HUMAN; IN VITRO STUDY; MAMMARY GLAND; MOLECULAR CLONING; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN STRUCTURE; XENOGRAFT;

EID: 0041386609     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00209-7     Document Type: Conference Paper

References (22)

1. G.T. Beaten, On the treatment of inoperable cases of carcinoma of the mamma: with suggestions for a new method of treatment, with illustrative cases, Lancet 2 (1896) 104-107.
2. Ali S., Combos R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer. 2:2002;101-112.
3. Early Breast Cancer Trialists' Collaborative Group, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet 351 (1998) 1451-1467.
4. A. Howell, New antiestrogens: modulators of estrogen action, in: J.-M. Nabholtz, K. Tonkin, M.S. Aapro, A.U. Buzdar (Eds.), Breast Cancer Management, Martin Dunitz Ltd., London, 2000, pp. 143-169.
5. Pasqualini J.R., Chetrite G., Blacker C.et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81:1996;1460-1464.
6. A.U. Buzdar, G.N. Hortobagyi, Aromatase inhibitors in the treatment of breast cancer, in: J.-M. Nabholtz, K. Tonkin, M.S. Aapro, A.U. Buzdar (Eds.), Breast Cancer Management, Martin Dunitz Ltd., London, 2000, pp. 171-180.
7. Wiseman L.R., Adkins J.C. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging. 13:1998;321-332.
8. The ATAC Trialists' Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet 359 (2002) 2131-2139.
9. Inoue S., Kondo S., Hashimoto M.et al. Isolation of estrogen receptor-binding sites in human genomic DNA. Nucleic Acids Res. 19:1991;4091-4096.
10. Watanabe T., Inoue S., Hiroi H.et al. Isolation of estrogen-responsive genes with a CpG island library. Mol. Cell. Biol. 18:1998;442-449.
11. Inoue S., Orimo A., Hosoi T.et al. Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc. Natl. Acad. Sci. U.S.A. 90:1993;11117-11121.
12. Pickart C.M. Mechanisms underlying ubiquitination. Ann. Rev. Biochem. 70:2001;503-533.
13. Jensen K., Shiels C., Freemont P.S. PML protein isoforms and the RBCC/TRIM motif. Oncogene. 20:2001;7223-7233.
14. Ruffner H., Joazeiro C.A., Hemmati D.et al. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5134-5139.
15. Orimo A., Inoue S., Ikeda K.et al. Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. Co-localization with estrogen receptor mRNA in target organs. J. Biol. Chem. 270:1995;24406-24413.
16. Inoue S., Urano T., Ogawa S.et al. Molecular cloning of rat efp: expression and regulation in primary osteoblasts. Biochem. Biophys. Res. Commun. 261:1999;412-418.
17. Ikeda K., Orimo A., Higashi Y., Muramatsu M., Inoue S. Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Lett. 472:2000;9-13.
18. Orimo A., Inoue S., Minowa O.et al. Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 96:1999;12027-12032.
19. Urano T., Saito T., Tsukui T., Fujita M., Hosoi T., Muramatsu M., Ouchi Y., Inoue S. Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth. Nature. 417:2002;871-875.
20. Chan T.A., Hermeking H., Lengauer C.et al. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature. 401:1999;616-620.
21. Vercoutter-Edouart A.S., Lemoine J., Le Bourhis X.et al. Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells. Cancer Res. 61:2001;76-80.
22. Umbricht C.B., Evron E., Gabrielson E.et al. Hypermethylation of 14-3-3σ (stratifin) is an early event in breast cancer. Oncogene. 20:2001;3348-3353.